Related Experiment Videos
Prostaglandin and tumor necrosis factor secretion by peritoneal macrophages isolated from normal and arthritic rats
A S Williams1, J P Camilleri, N Topley
1Department of Rheumatology, University of Wales College of Medicine Cardiff, U.K.
Abstract:
The effect of a novel liposomal preparation containing a phospholipid conjugate of methotrexate (MTX-LIPO) upon macrophage mediator release was investigated in normal and arthritic rats ex vivo. Peritoneal macrophages isolated from MTX-LIPO-treated arthritic rats and stimulated with lipopolysaccharide produced significantly less tumor necrosis factor (TNF) and prostaglandin (PGE2) than did macrophages isolated from saline-treated controls. In the same experimental system, free methotrexate only inhibited prostaglandin release, but it was more potent than MTX-LIPO in this respect. Additional studies are presently underway to investigate the effect of MTX-LIPO and MTX treatment upon the lipopolysaccharide-induced rise in plasma levels of various proinflammatory mediators in vivo. Haematopoietic toxicity was demonstrated in blood isolated from rats treated with free MTX, and this was as characterized by a significant reduction in reticulocyte count compared with MTX-LIPO and saline-treated rats.
Insights
A novel liposomal methotrexate (MTX-LIPO) preparation reduced inflammatory mediators from macrophages in arthritic rats. Free methotrexate was more potent for prostaglandin inhibition but caused greater hematopoietic toxicity.
Area of Science:
- Pharmacology
- Immunology
- Drug Delivery Systems
Background:
- Macrophages play a key role in inflammatory mediator release during arthritis.
- Methotrexate (MTX) is a common treatment for inflammatory conditions, but its delivery and toxicity are concerns.
Purpose of the Study:
- To investigate the efficacy of a novel liposomal methotrexate conjugate (MTX-LIPO) on macrophage mediator release.
- To compare the effects of MTX-LIPO with free methotrexate (MTX) in an ex vivo arthritis model.
- To assess the hematopoietic toxicity of MTX-LIPO versus free MTX.
Main Methods:
- Ex vivo study using peritoneal macrophages isolated from normal and arthritic rats.
- Macrophages were treated with MTX-LIPO or saline, then stimulated with lipopolysaccharide.
- Measurement of tumor necrosis factor (TNF) and prostaglandin E2 (PGE2) release.
- Assessment of reticulocyte counts in blood from treated rats.
Main Results:
- MTX-LIPO significantly reduced TNF and PGE2 release from lipopolysaccharide-stimulated macrophages in arthritic rats compared to controls.
- Free MTX inhibited prostaglandin release more potently than MTX-LIPO.
- Free MTX treatment led to significant hematopoietic toxicity, evidenced by reduced reticulocyte counts, unlike MTX-LIPO.
Conclusions:
- MTX-LIPO effectively suppresses key inflammatory mediators released by macrophages in an arthritic model.
- MTX-LIPO demonstrates a potentially improved safety profile regarding hematopoietic toxicity compared to free MTX.
- Further in vivo studies are warranted to confirm these findings and evaluate plasma mediator levels.